A guide to interpretation of neuroimmunological biomarkers in the combined antiretroviral therapy-era of HIV central nervous system disease

Katrina A MorrisDepartment of Neurology, St. Vincent’s Hospital, Sydney, Australia and St. Vincent’s Centre for Applied Medical Research, Sydney, New South Wales, Australia

Nicholas WS DaviesDepartment of Neurology, St. Vincent’s Hospital, Sydney, Australia and St. Vincent’s Centre for Applied Medical Research, Sydney, New South Wales, Australia

Bruce J BrewDepartment of Neurology, St. Vincent’s Hospital, Sydney, Australia and St. Vincent’s Centre for Applied Medical Research, Sydney, New South Wales, AustraliaCorrespondence[email protected]

Abstract:

Biomarkers have emerging roles in diagnosis, prognostication, and treatment monitoring in patients with human immunodeficiency virus-related central nervous system disease. Currently, it is unlikely that a single biomarker will be able to fulfill these roles; rather a combination is more likely. In this review, we use a pathogenetic framework to discuss biomarkers derived from both the blood and cerebrospinal fluid. Emphasis is given to those biomarkers that have a more solid evidence base and those that are easily measurable.

Keywords::

A guide to interpretation of neuroimmunological biomarkers in the combined antiretroviral therapy-era of HIV central nervous system disease

Information for

Open access

Opportunities

Help and information

A guide to interpretation of neuroimmunological biomarkers in the combined antiretroviral therapy-era of HIV central nervous system disease

Abstract:

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature